Inogen, Inc. (INGN)
NASDAQ: INGN · Real-Time Price · USD
6.80
-0.34 (-4.76%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Company Description
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.
It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Inogen, Inc.
| Country | United States |
| Founded | 2001 |
| IPO Date | Feb 14, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 766 |
| CEO | Kevin R. Smith |
Contact Details
Address: 859 Ward Drive Goleta, California 93111 United States | |
| Phone | 805 562 0500 |
| Website | provider.inogen.com |
Stock Details
| Ticker Symbol | INGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001294133 |
| CUSIP Number | 45780L104 |
| ISIN Number | US45780L1044 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Kevin R. M. Smith | President, Chief Executive Officer and Director |
| Michael J. Bourque CPA | Executive Vice President, Chief Financial Officer and Treasurer |
| Philip Corrin | Senior Vice President of Operations and Supply Chain |
| Kevin P. Smith | General Counsel, Secretary and Executive Vice President of Business Development |
| Jennifer Yi Boyer | Executive Vice President and Chief Human Resources Officer |
| Grgoire Ramade | Executive Vice President and Chief Commercial Officer |
| Dr. Krishna Jhaveri | Chief Medical Officer |
| Paul Andreassi | Senior Vice President of Quality and Regulatory Affairs |
| Adrien Mithalal | Senior Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | ARS | Filing |
| Mar 27, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 24, 2025 | SCHEDULE 13G | Filing |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |